Antonio Bastardo’s career was twice derailed by performance-enhancing-drug suspensions. In August 2013, while pitching as one of the Philadelphia Phillies’ most effective relief arms, Bastardo received a 50-game suspension from Major League Baseball as part of the Biogenesis investigation. The scandal centered on the Miami-area Biogenesis clinic and its operator, Anthony Bosch, whose records implicated numerous professional baseball players in the use or purchase of banned substances. Bastardo was 3–2 with a 2.32 ERA when the suspension was announced, meaning Philadelphia lost a productive bullpen piece for the remainder of the season and Bastardo’s reputation became tied to one of baseball’s defining doping scandals of the era.
The episode was not an isolated blemish. After later stops with the Pittsburgh Pirates and New York Mets, Bastardo tested positive for stanozolol, an anabolic steroid associated with performance enhancement, and MLB suspended him for 140 games on July 20, 2018. The punishment came after he had signed a minor-league contract with the Arizona Diamondbacks and was released before the 2018 season began, effectively closing the door on his major-league career. His two suspensions—one connected to the Biogenesis network and the other to a confirmed stanozolol test—made him a rare repeat offender in the post-testing era and overshadowed an otherwise substantial career as a left-handed setup and relief pitcher.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.